BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 18067631)

  • 1. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head.
    Stockfleth E; Sterry W; Carey-Yard M; Bichel J
    Br J Dermatol; 2007 Dec; 157 Suppl 2():41-6. PubMed ID: 18067631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
    Korman N; Moy R; Ling M; Matheson R; Smith S; McKane S; Lee JH
    Arch Dermatol; 2005 Apr; 141(4):467-73. PubMed ID: 15837864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients.
    Ulrich C; Bichel J; Euvrard S; Guidi B; Proby CM; van de Kerkhof PC; Amerio P; Rønnevig J; Slade HB; Stockfleth E
    Br J Dermatol; 2007 Dec; 157 Suppl 2(Suppl 2):25-31. PubMed ID: 18067628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up.
    Krawtchenko N; Roewert-Huber J; Ulrich M; Mann I; Sterry W; Stockfleth E
    Br J Dermatol; 2007 Dec; 157 Suppl 2():34-40. PubMed ID: 18067630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases.
    Stockfleth E; Meyer T; Benninghoff B; Christophers E
    Br J Dermatol; 2001 May; 144(5):1050-3. PubMed ID: 11359396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head.
    Rivers JK; Rosoph L; Provost N; Bissonnette R
    J Cutan Med Surg; 2008; 12(3):97-101. PubMed ID: 18544290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head.
    Alomar A; Bichel J; McRae S
    Br J Dermatol; 2007 Jul; 157(1):133-41. PubMed ID: 17501955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of multiple, multiform actinic keratoses on the head with imiquimod 5% cream.
    Stockfleth E; Ulrich C; Lange-Asschenfeldt B; Kremer HJ; Drecoll U; Maus J; Röwert-Huber J
    Eur J Dermatol; 2009; 19(4):355-9. PubMed ID: 19467962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head.
    Jorizzo J; Dinehart S; Matheson R; Moore JK; Ling M; Fox TL; McRae S; Fielder S; Lee JH
    J Am Acad Dermatol; 2007 Aug; 57(2):265-8. PubMed ID: 17512087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
    Gebauer K; Shumack S; Cowen PS
    Br J Dermatol; 2009 Oct; 161(4):897-903. PubMed ID: 19545297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.
    Lebwohl M; Dinehart S; Whiting D; Lee PK; Tawfik N; Jorizzo J; Lee JH; Fox TL
    J Am Acad Dermatol; 2004 May; 50(5):714-21. PubMed ID: 15097955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on actinic keratosis in clinical trial experience with imiquimod.
    Ferrándiz C
    Br J Dermatol; 2007 Dec; 157 Suppl 2():32-3. PubMed ID: 18067629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases.
    Ulrich C; Busch JO; Meyer T; Nindl I; Schmook T; Sterry W; Stockfleth E
    Br J Dermatol; 2006 Aug; 155(2):451-4. PubMed ID: 16882188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
    Quirk C; Gebauer K; Owens M; Stampone P
    Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
    Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
    Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis.
    Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z
    J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5% topical imiquimod tolerance in transplant recipients.
    Ben M'barek L; Mebazaa A; Euvrard S; Frances C; Thervet E; Morel P; Menasché S; Legendre C; Lebbe C
    Dermatology; 2007; 215(2):130-3. PubMed ID: 17684375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses.
    Stockfleth E; Meyer T; Benninghoff B; Salasche S; Papadopoulos L; Ulrich C; Christophers E
    Arch Dermatol; 2002 Nov; 138(11):1498-502. PubMed ID: 12437457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.